Speransa Therapeutics is a German clinical-stage biopharmaceutical company, focusing on the development of innovative second-generation COVID-19 vaccines based on the ORF Virus vector platform.
Prime-2-CoV_Beta, our lead COVID-19 vaccine candidate, is entering a Phase 1 clinical study in Q2 2022.
.jpg)
The protection conferred by current single-antigen expressing COVID-19 vaccines is declining over time. Our approach, combining the expression of Spike and Nucleoprotein in a single vector, aims at triggering a better induction of the cellular arm of immunity, thus extending the duration of the protection conferred by the vaccine. In addition, the induction of a strong cellular immunity is needed to better address the emergence of new SARS-CoV-2 variants.
Read more about our TechnologyORFEUS is the name of the dose-finding study assessing the safety, tolerability and immunogenicity of a two-dose regimen of our lead COVID-19 vaccine candidate Prime-2-CoV_Beta.
Speransa Therapeutics' pipeline comprises vaccine candidates derived from the attenuated second generation ORF virus vaccine platform to target the unmet needs of the COVID-19 pandemic. Our clinical-stage COVID-19 vaccine candidate is based on the SARS-CoV-2 Beta Variant. In addition to that, we are working on vaccines targeting the Delta and Omicron variants, as well as multivalent vaccines.
Read more about our PipelineThrough R&D collaborations and partnerships with pharmaceutical and biotech companies as well as academia and clinics, we aim to fully leverage our technology with cutting edge science and advance vaccine research and development.
